NovImmune Nominates Klaus Strein as New Member of the Board of Directors
After BM was taken over by Roche in 1998, Prof Strein moved first to Basel and then to Penzberg (Germany), where in 1998/99 he became Head of Pharma Research. In 2001/2002, Prof Strein and his team in Penzberg launched the Roche Therapeutic Protein Initiative. Prof Strein was assigned global responsibility for the generation and molecular engineering of therapeutic proteins/monoclonal antibodies at Roche.
In August 2009, Prof Strein moved to Basel and took over as ad interim Global Head of Pharma Research; he was instrumental in the formation of the new global division Pharma Research and Early Development (pRED) in early 2010. Since January 2010, he is in charge of all Pharma Research and Early Development (pRED) activities in connection with the generation, optimization, early technical development and formulation of small molecules, therapeutic proteins, RNA therapeutics and therapeutic stem cells.
Prof Strein commented that ‘it is a great opportunity to become part of an already well established biotech like NovImmune where technologies and products will potentially deliver superior treatment modalities to ill-served patient populations.’
Jack Barbut, CEO, commented that ‘I am very pleased that NovImmune was able to attract such a high caliber personality from the pharma world. The nomination of Prof Strein as new Board member will strengthen and widen the expertise of the current team, and will be an important asset for supporting and implementing NovImmune’s corporate development’.
About NovImmune SA
NovImmune SA (‘NovImmune’) is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders. NovImmune has generated, to date, seven proprietary mAbs. The pipeline is a balance of preclinical and clinical compounds, with a mix of both clinically validated as well as novel targets. Each of these portfolio products has the potential to become a medicine for multiple medical conditions due to the overlapping mechanism of action under laying these types of diseases. Three compounds are at this time in clinical development, with the most advanced in Phase II. Moreover, NovImmune also created a platform for the generation of fully human mono-, pan- and bispecific antibodies.
For more information please visit our website: www.novimmune.com
Contact Jack Barbut CEO NovImmune SA 14 ch. des Aulx 1228 Plan-Les-Ouates, Geneva Switzerland
T +41 22 839 71 41 F +41 22 839 71 43
Luca Bolliger Director, Business Development NovImmune SA 14 ch. des Aulx 1228 Plan-Les-Ouates, Geneva Switzerland T +41 22 593 51 15 F +41 22 839 71 43
Please login or sign up to comment.
Commenting guidelines